CN1006331B - 提取细胞内环核苷酸的方法 - Google Patents
提取细胞内环核苷酸的方法Info
- Publication number
- CN1006331B CN1006331B CN 87106203 CN87106203A CN1006331B CN 1006331 B CN1006331 B CN 1006331B CN 87106203 CN87106203 CN 87106203 CN 87106203 A CN87106203 A CN 87106203A CN 1006331 B CN1006331 B CN 1006331B
- Authority
- CN
- China
- Prior art keywords
- cell
- cyclic nucleotide
- glucose
- suspension
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- 239000002773 nucleotide Substances 0.000 title abstract description 5
- 125000003729 nucleotide group Chemical group 0.000 title abstract description 5
- 238000010438 heat treatment Methods 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 26
- 125000004122 cyclic group Chemical group 0.000 claims description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 239000006285 cell suspension Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002608 ionic liquid Substances 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 210000002381 plasma Anatomy 0.000 claims description 5
- 239000011159 matrix material Substances 0.000 claims description 4
- 238000004062 sedimentation Methods 0.000 claims description 4
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 5
- 238000006911 enzymatic reaction Methods 0.000 abstract description 4
- 238000000605 extraction Methods 0.000 abstract description 3
- 239000012528 membrane Substances 0.000 description 11
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 238000011112 process operation Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 208000035199 Tetraploidy Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
- 229940005991 chloric acid Drugs 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- -1 glucose ion Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
Abstract
一种提取细胞内环核苷酸的方法,不需要破膜,也不受温度和试剂的影响,而是通过加热,在终止酶反应的同时提取细胞内的环核苷酸,操作简便快速,提取结果准确,易于推广应用。
Description
本发明是关于小分子物质的提取方法,特别是关于提取细胞内环核苷酸的方法。
环核苷酸在细胞功能调节中起重要作用,是一项不可缺少的分子学指标。目前,对提取细胞内环核苷酸,常采用的是冻融裂解法、超声波破膜法、低渗破膜法和匀浆破膜法等。
冻融裂解法是通过将细胞反复冻融,使细胞膜破裂而释放出环核苷酸,采用此法时必须在细胞悬液中加磷酸二酯酶抑制剂(EDTA),以防止环磷酸腺苷(CAMP)和环磷酸乌苷(CGMP)被磷酸二酯酶(PDE)水解,酶抑制剂的存在,虽然PDE被抑制,但使细胞内其他酶类未被灭活,易受冻融温度和EDTA的交互影响,从而影响细胞内环核苷酸的含量,特别是对CGMP的影响,使其含量偏高。
超声波破膜法是通过超声波发生器机械性破细胞膜,释放出环核苷酸。该法需用三氯醋酸或高氯酸终止酶反应,但细胞的膜蛋白经酸固定后会影响破膜率,并且在破膜后须用水饱和乙醚提取三氯醋酸或用碱中和高氯酸。整个提取过程操作步骤多而复杂,易造成实验误差大,并且受到仪器设备限制,不易推广应用。
低渗破膜法采用细胞悬液中加水低渗、破膜,然后加热和加酸去蛋白,由于终止酶反应前细胞受到低渗刺激,影响环核苷酸的含量,加之须除去膜蛋白和提取酸,否则环核苷酸含量偏高。
匀浆破膜法是在自然沉降后的血浆中加蒸馏水低渗破坏红细胞,然后用氯化钠溶液恢复等渗,离心后的沉淀细胞用Tris缓冲液
(含EDTA)制成细胞悬液,其释放环核苷酸的方法是在上述细胞悬液中加过氯酸,再用匀浆器匀浆机械破细胞膜,离心去膜蛋白,其上清液再加碱中和酸,再离心去盐,然后取上清液经阴离子交换树脂分别洗脱收集环核苷酸。
用上述各方法提取细胞内环核苷酸,都是经过细胞分离处理,除去红细胞,制成细胞悬液后,采用不同手段破膜,以使细胞内环核苷酸释放出来,再经分离得到环核苷酸,其中都需要加一定的试剂。膜蛋白和试剂的存在,以及温度的变化,影响了环核苷酸的含量。由于提取过程操作步骤多而复杂,易造成实验系统误差大,而且所需仪器设备要求高,不易推广应用。
本发明的目的是建立一种操作简单,易推广,不受温度和试剂影响的提取细胞内环核苷酸的稳定方法。
本发明采用加热提取细胞内环核苷酸的方法,是将自然沉降后的血浆经低渗破坏红细胞后立即恢复等渗,离心去血红蛋白等,离心后的沉淀细胞以0.1%葡萄糖等渗离子液为基质,制成细胞悬液,将该细胞悬液置于80°~100℃水浴加热5~40分钟,冰浴冷却,经离心分离的上清液即含环核苷酸。
0.1%葡萄糖等渗离子液组成为:138mM NaCl 2.7mMKCl 8.1mM Na2HPO41.5mM KH2PO41mM MgCl20.6mM CaCl20.1%葡萄糖液PH7.4。
本发明是在加热终止酶反应的同时,提取细胞内的环核苷酸,提取时不需要加EDTA和其它试剂,可以消除酶抑制剂等试剂和温度变化对细胞内环核苷酸含量的影响;并且采用等渗离子液为基质以提高细胞存活率,特别是不经过破膜,其可溶性蛋白小于100微克/107细
胞,因此不需要除蛋白。整个操作简便,结果稳定,可以减少实验的系统误差,提高结果准确性,易于推广。并且还适用于提取血小板内的环核苷酸,以及作体外抗炎、免疫、药理等实验研究。
本发明的实施例是这样的:抗凝血置室温下自然沉降30~40分,吸出富有白细胞的血浆,根据标本要求分别分离白细胞、淋巴细胞、血小板等。若处理白细胞、淋巴细胞,则分别取富有白细胞的血浆沉淀物和淋巴细胞分离后的沉淀物,用少量生理盐水悬浮,加四倍体积的蒸馏水低渗30秒~2分钟(视标本对象而定)破坏红细胞,立即加3.6%氯化钠恢复等渗,再离心去血红蛋白等,取沉淀物加0.1%葡萄糖等渗离子液洗2次,取其细胞悬液分装试管内,置80°~100℃水浴,加热5~40分钟,取出试管,放入冰浴冷却,然后经3000rpm离心10分钟,上清液即含环核苷酸。可直接定量吸取上清液,加上一定量的氚标抗原和一定稀释量的抗体,作放射免疫竞争反应,测定环核苷酸的含量。也可以将上清液定量吸入小烧杯中,置65℃水浴蒸干,放入冰箱保存,待测环核苷酸,保存期可达2~3个月。
进行细胞分离处理所用的0.1%葡萄糖离子液的组成是:
138mM NaCl 2.7mM KCl
8.1mM Na2HPO41.5mM KH2PO4
1mM MgCl20.6mM CaCl2
0.1%葡萄糖液,PH7.4。
用该离子液做基质,可以提高细胞存活率。
Claims (1)
1、一种提取细胞内环核苷酸的方法,包括将自然沉降的血浆加蒸馏水低渗30~120秒,立即用氯化钠渗液恢复等渗,离心,取沉淀细胞制成细胞悬液,从悬浮细胞内释放出环核苷酸,分离得到环核苷酸,其特征在于:沉淀细胞用0.1%葡萄糖等渗离子液为基质制成细胞悬液,0.1%葡萄糖等渗离子液组成为:
138mM NaCl 2.7mM KCl 8.1mM Na2HPO4
1.5mM KH2PO41mM MgCl20.6mM CaCl2
0.1%葡萄糖液 PH7.4,然后将该细胞悬液置于80°~100℃水浴加热5~40分钟后,冰浴冷却,离心分离后的上清液即含环核苷酸。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 87106203 CN1006331B (zh) | 1987-09-05 | 1987-09-05 | 提取细胞内环核苷酸的方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 87106203 CN1006331B (zh) | 1987-09-05 | 1987-09-05 | 提取细胞内环核苷酸的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1032032A CN1032032A (zh) | 1989-03-29 |
| CN1006331B true CN1006331B (zh) | 1990-01-03 |
Family
ID=4815620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 87106203 Expired CN1006331B (zh) | 1987-09-05 | 1987-09-05 | 提取细胞内环核苷酸的方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1006331B (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1110567C (zh) * | 2000-02-17 | 2003-06-04 | 北京太宫生物技术有限责任公司 | 脱氧核糖核苷三磷酸的制备方法 |
| CN1322142C (zh) * | 2004-10-22 | 2007-06-20 | 哈尔滨医科大学 | 提取dna的试剂及使用该试剂提取哺乳动物dna的方法 |
| CN105647995B (zh) * | 2016-02-29 | 2019-03-08 | 山东大学 | 一种提取2′,3′-环形核苷单磷酸的方法 |
-
1987
- 1987-09-05 CN CN 87106203 patent/CN1006331B/zh not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| CN1032032A (zh) | 1989-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wolf | The nature and significance of platelet products in human plasma | |
| Hovig | Aggregation of rabbit blood platelets produced in vitro by saline “extract” of tendons | |
| Magee et al. | The purification and properties of phospholipase A from human pancreas | |
| Himmelhoch et al. | Purification of myeloperoxidases from bone marrow | |
| Tamm et al. | A mucoprotein derived from human urine which reacts with influenza, mumps, and Newcastle disease viruses | |
| Neal Pinckard et al. | Physicochemical and functional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE sensitized basophils | |
| Tan | An immunologic precipitin system between soluble nucleoprotein and serum antibody in systemic lupus erythematosus | |
| Hanahan et al. | The expression of optimum ATPase activities in human erythrocytes: A comparison of different lytic procedures | |
| Kapp et al. | Cerebral Arterial Spasm: Part 3: Partial Purification and Characterization of a Spasmogenic Substance in Feline Platelets | |
| Ts'o et al. | Observations on an ATP-sensitive protein system from the plasmodia of a myxomycete | |
| Johnson et al. | Comparison of several methods for isolation of rat peritoneal mast cells. | |
| Warnock | Characterization of tissue and serum alkaline phosphatases | |
| Moskowitz et al. | Studies on the Antigens of Human Red Cells: I. The Separation from Human Erythrocytes of a Qater Soluble Fraction Containing the Rh, a and b Factors | |
| Curtain | The nature of the protein in the hyaluronic complex of bovine synovial fluid | |
| CN110411816B (zh) | 一种外泌体的富集方法 | |
| Hecht et al. | Thromboplastin: Nomenclature and preparation of protein-free material different from platelet factor 3 or lipid activator | |
| Rafter et al. | STUDIES ON THE PATHOGENESIS OF FEVER: XIV. Further Observations on the Chemistry of Leukocytic Pyrogen | |
| Pigman et al. | Interactions of hyaluronic acid with serum albumin | |
| Silcox et al. | Identification of inorganic pyrophosphate in human platelets and its release on stimulation with thrombin | |
| Price et al. | The nature of the alkaline phosphatases of bile | |
| Smith | The phosphatides of the latex of Hevea brasiliensis. 1. Biochemical changes | |
| CN1032032A (zh) | 提取细胞内环核苷酸的方法 | |
| Dounce et al. | Action of mitochondrial DNAase I in destroying the capacity of isolated cell nuclei to form gels | |
| Mackay | The fractionation of mammalian serum proteins with ether | |
| Peck et al. | Effect of heat on the conversion of di‐2‐ethylhexyl phthalate to mono‐2‐ethylhexyl phthalate in human plasma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C13 | Decision | ||
| GR02 | Examined patent application | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |